Brexpiprazole for the Treatment of Schizophrenia in Adults: An Overview of Its Clinical Efficacy and Safety and a Psychiatrist’s Perspective

References

• SahaS, ChantD, WelhamJ, McGrathJW. A systematic review of the prevalence of schizophrenia. PLoS Med. 2005;2(5):e141. doi:10.1371/journal.pmed.002014115916472
   PubMed Web of Science ®Google Scholar
• SimeoneJC, WardAJ, RotellaP, CollinsJ, WindischR. An evaluation of variation in published estimates of schizophrenia prevalence from 1990─2013: a systematic literature review. BMC Psychiatry. 2015;15:193. doi:10.1186/s12888-015-0578-726263900
   PubMed Web of Science ®Google Scholar
• SadoM, InagakiA, KorekiA, et al. The cost of schizophrenia in Japan. Neuropsychiatr Dis Treat. 2013;9:787–798. doi:10.2147/NDT.S4163223785238
   PubMed Web of Science ®Google Scholar
• CiompiL. Is there really a schizophrenia? The long-term course of psychotic phenomena. Br J Psychiatry. 1984;145(6):636–640. doi:10.1192/bjp.145.6.6366210125
   PubMed Web of Science ®Google Scholar
• HardingCM, ZubinJ, StraussJS. Chronicity in schizophrenia: fact, partial fact, or artifact? Hosp Community Psychiatry. 1987;38(5):477–486.3297969
   PubMedGoogle Scholar
• HuhnM, NikolakopoulouA, Schneider-ThomaJ, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394(10202):939–951. doi:10.1016/S0140-6736(19)31135-331303314
   PubMed Web of Science ®Google Scholar
• DiefenderferLA, IuppaC. Brexpiprazole: a review of a new treatment option for schizophrenia and major depressive disorder. Ment Health Clin. 2017;7(5):207–212. doi:10.9740/mhc.2017.09.20729955525
   PubMedGoogle Scholar
• KaneJM. Treatment strategies to prevent relapse and encourage remission. J Clin Psychiatry. 2007;68(Suppl 14):27–30.
   PubMed Web of Science ®Google Scholar
• IvkovicJ, LindstenA, GeorgeV, ErikssonH, HobartM. Effect of brexpiprazole on prolactin: an analysis of short- and long-term studies in schizophrenia. J Clin Psychopharmacol. 2019;39(1):13–19. doi:10.1097/JCP.000000000000097930566415
   PubMed Web of Science ®Google Scholar
• AmadaN, AkazawaH, OhgiY, et al. Brexpiprazole has a low risk of dopamine D2 receptor sensitization and inhibits rebound phenome related to D2 and serotonin 5-HT2A receptors in rats. Neuropsychopharmacol Rep. 2019;39(4):279–288. doi:10.1002/npr2.1207631487433
   PubMedGoogle Scholar
• CitromeL, OtaA, NagamizuK, PerryP, WeillerE, BakerRA. The effect of brexpiprazole (OPC-34712) and aripiprazole in adult patients with acute schizophrenia: results form a randomized, exploratory study. Int Clin Psychomaracol. 2016;31(4):192–201. doi:10.1097/YIC.0000000000000123
   PubMed Web of Science ®Google Scholar
• CarlssonA, KehrW, LindqvistM, MagnussonT, AtackCV. Regulation of monoamine metabolism in the central nervous system. Pharmacol Rev. 1972;24(2):371–384.4564607
   PubMed Web of Science ®Google Scholar
• KikuchiT, TottoriK, UwahodoY, et al. 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exp Ther. 1995;274(1):329–336.7616416
   PubMed Web of Science ®Google Scholar
• MaedaK, SuginoH, AkazawaH, et al. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 2014;350(3):589–604. doi:10.1124/jpet.114.21379324947465
   PubMed Web of Science ®Google Scholar
• MaedaK, LerdrupL, SuginoH, et al. Brexpiprazole II: antipsychotic-like and pro-cognitive effects of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 2014;350(3):605–614. doi:10.1124/jpet.114.21381924947464
   PubMed Web of Science ®Google Scholar
• YoshimiN, FujitaY, OhgiY, FutamuraT, KikuchiT, HashimotoK. Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-HT1A receptors. Pharmacol Biochem Behav. 2014;124:245–249. doi:10.1016/j.pbb.2014.06.00824955861
   PubMed Web of Science ®Google Scholar
• CorrellCU, SkubanA, HobartM, et al. Efficacy of brexpiprazole in patients with acute schizophrenia: review of three randomized, double-blind, placebo-controlled studies. Schizophr Res. 2016;174(1–3):82–92. doi:10.1016/j.schres.2016.04.01227157799
   PubMed Web of Science ®Google Scholar
• MarderSR, HakalaMJ, JosiassenMK, et al. Brexpiprazole in patients with schizophrenia: overview of short- and long-term Phase 3 controlled studies. Acta Neuropsychiatr. 2017;29(5):278–290. doi:10.1017/neu.2016.5727846922
   PubMed Web of Science ®Google Scholar
• IshigookaJ, IwashitaS, TadoriY. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia in Japan: a 6-week, randomized, double-blind, placebo-controlled study. Psychiatry Clin Neurosci. 2018;72(9):692–700. doi:10.1111/pcn.1268229774628
   PubMed Web of Science ®Google Scholar
• CorrellCU, SkubanA, OuyangJ, et al. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2015;172(9):870–880. doi:10.1176/appi.ajp.2015.1410127525882325
   PubMed Web of Science ®Google Scholar
• KaneJM, SkubanA, OuyangJ, et al. A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia. Schizophr Res. 2015;164(1–3):127–135. doi:10.1016/j.schres.2015.01.03825682550
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. NCT01810380. Available from: https://clinicaltrials.gov/ct2/show/NCT01810380?term=NCT01810380&draw=1&rank=1. Accessed 10 18, 2020.
   Google Scholar
• van ErpTG, BakerRA, CoxK, et al. Effect of brexpiprazole on control of impulsivity in schizophrenia: a randomized functional magnetic resonance imaging study. Psychiatry Res Neuroimaging. 2020;301:111085. doi:10.1016/j.pscychresns.2020.11108532450497
   PubMed Web of Science ®Google Scholar
• MallaA, OtaA, NagamizuK, PerryP, WeillerE, BakerRA. The effect of brexpiprazole in adult outpatients with early-episode schizophrenia: an exploratory study. Int Clin Psychopharmacol. 2016;31(6):307–314. doi:10.1097/YIC.000000000000014027571460
   PubMed Web of Science ®Google Scholar
• FleischhackerWW, HobartM, OuyangJ, et al. Efficacy and safety of brexpiprazole (OPC-34712) as maintenance treatment in adults with schizophrenia: a randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol. 2017;20(1):11–21.27566723
   PubMed Web of Science ®Google Scholar
• ForbesA, HobartM, OuyangJ, ShiL, PfisterS, HakalaM. A long-term, open-label study to evaluate the safety and tolerability of brexpiprazole as maintenance treatment in adults with schizophrenia. Int J Neuropsychopharmacol. 2018;21(5):433–441. doi:10.1093/ijnp/pyy00229415258
   PubMed Web of Science ®Google Scholar
• Ishigooka J, Iwashita S, Tadori Y. Long-term safety and effectiveness of brexpiprazole in Japanese patients with schizophrenia: A 52-week, open-label study. Psychiatry Clin Neurosci. 2018;72(6):445–453.29582518
   PubMed Web of Science ®Google Scholar
• YoshimuraY, ShimizuH, YamashitaR, WashidaK, TakedaT, AokiS. Association between previous high-dose antipsychotic therapy and brexpiprazole discontinuation after the initiation of brexpiprazole in patients with schizophrenia or schizoaffective disorder. Int Clin Psychopharmacol. 2020;35(2):98–104. doi:10.1097/YIC.000000000000029631743231
   PubMed Web of Science ®Google Scholar
• YanT, GreeneM, ChangE, et al. Health care cost in patients with schizophrenia treated with brexpiprazole versus other oral atypical antipsychotic therapy. Clin Ther. 2020;42(1):77-93. doi:10.1016/j.clinthera.2019.11.009
   Google Scholar
• YangS, ChenL, NajoanE, et al. Polypharmacy and psychotropic drug loading in patients with schizophrenia in Asian countries: fourth survey of Research on Asian Prescription Patterns on antipsychotics. Psychiatry Clin Neurosci. 2018;72(8):572–579. doi:10.1111/pcn.1267629761577
   PubMed Web of Science ®Google Scholar
• KaneJM, SkubanA, HobartM, et al. Overview of short- and long-term tolerability and safety of brexpiprazole in patients with schizophrenia. Schizophr Res. 2016;174(1–3):93–98. doi:10.1016/j.schres.2016.04.01327188270
   PubMed Web of Science ®Google Scholar
• WeissC, WeillerE, BakerRA, et al. The effects of brexpiprazole and aripiprazole on body weight as monotherapy in patients with schizophrenia and as adjunctive treatment in patients with major depressive disorder: an analysis of short-term and long-term studies. Int Clin Psychopharmacol. 2018;33(5):255–260. doi:10.1097/YIC.000000000000022629878915
   PubMed Web of Science ®Google Scholar
• NewcomerJW, ErikssonH, ZhangP, WeillerE, WeissC. Changes in metabolic parameters and body weight in brexpiprazole-treated patients with acute schizophrenia: pooled analyses of phase 3 clinical studies. Curr Med Res Opin. 2018;34(12):2197–2205. doi:10.1080/03007995.2018.149877929985680
   PubMed Web of Science ®Google Scholar
• CorrellCU, ShiL, WeissC, et al. Successful switching of patients with acute schizophrenia from another antipsychotic to brexpiprazole: comparison of clinicians’ choice of cross-titration schedules in a post hoc analysis of a randomized, double-blind, maintenance treatment study. CNS Spectr. 2019;24(5):507–517. doi:10.1017/S109285291800108630306884
   PubMed Web of Science ®Google Scholar
• YanT, GreeneM, ChangE, et al. Health care cost in patients with schizophrenia treated with brexpiprazole versus other oral atypical antipsychotic therapy. Clin Ther. 2020;42(1):77–93. doi:10.1016/j.clinthera.2019.11.00931928831
   PubMed Web of Science ®Google Scholar
• WolfersT, DoanNT, KaufmannT, et al. Mapping the heterogeneous phenotype of schizophrenia and bipolar disorder using normative models. JAMA Psychiatry. 2018;75(11):1146–1155. doi:10.1001/jamapsychiatry.2018.246730304337
   PubMed Web of Science ®Google Scholar
• WatanabeY, UrakamiT, HongoS, OhtsuboT. Frontal lobe function and social adjustment in patients with schizophrenia: near-infrared spectroscopy. Hum Psychopharmacol. 2015;30(1):28–41. doi:10.1002/hup.244825408137
   PubMed Web of Science ®Google Scholar
• WatanabeY, AzekawaT, HongoS, DoiN, IjiriS, HidaH. Multicenter study on reintegration of ambulatory schizophrenia patients: preliminary investigation and data analysis for a cohort study (report 1). J New Rem Clin. 2015;64(11):1389–1401.
   Google Scholar
• LeuchtS, KomossaK, Rummel-KlugeC, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry. 2009;166(2):152–163. doi:10.1176/appi.ajp.2008.0803036819015230
   PubMed Web of Science ®Google Scholar
• HealyD, Le NouryJ, HarrisM, et al. Mortality in schizophrenia and related psychoses: data from two cohorts, 1875–1924 and 1994–2010. BMJ Open. 2012;2(5):e001810. doi:10.1136/bmjopen-2012-001810
   PubMed Web of Science ®Google Scholar